Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ironwood Pharmaceuticals Inc.

www.ironwoodpharma.com

Latest From Ironwood Pharmaceuticals Inc.

On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study

Arena announced encouraging data from a small Phase IIa study for olorinab (APD371) in abdominal pain associated with Crohn's disease as the company continues a streak of good news after two of its more advanced clinical-stage programs posted positive results.

Business Strategies Clinical Trials

US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Drug Review Gastrointestinal

Key Drug Launches To Plan For In 2019

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Approvals Launches

Japan Approval Another Boost For Tagrisso in 1L NSCLC

Following a priority review, Japan has approved AstraZeneca’s Tagrisso for the first-line treatment of inoperable or recurrent EGFR mutation-positive NSCLC, further strengthening the drug’s position in this setting.

Japan Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Alias(es)
  • Microbia Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ironwood Pharmaceuticals Inc.
  • Senior Management
  • Peter M Hecht, PhD, CEO
    Gina Consylman, SVP, CFO
    Mark G Currie, PhD, SVP, CSO & Pres., R&D
    Christopher Wright, MD, PhD, SVP, Global Dev. & Chief Dev. Officer
    Thomas McCourt, Chief Commercial Officer & SVP, Mktg. & Sales
  • Contact Info
  • Ironwood Pharmaceuticals Inc.
    Phone: (617) 621-7722
    301 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register